Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH Forward Trial Demonstrating that TransCon™ PTH Provided Durable Benefit and Was Well-Tolerated in Adults with Hypoparathyroidism
–– 58 of the original 59 subjects continue in the open-label extension portion of the…
MODA & JAECOO Unveil 2027 “From Million To Annual Million” Strategy, Powering Chery’s Next Phase of Global Growth
Rozee Digital Helps Health and Beauty Brand Scale from $300K to $2M Per Month with Creative Strategy
Lithosphere to Launch Devnet Environment for Scalable AI Application Testing
GridAI Technologies Corp. Announces Receipt of NASDAQ Notice Regarding Late Form 10-K Filing
AISIX Solutions Inc. Announces Upsize of Non-Brokered Private Placement of Shares